Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
Three Targeted Agents in Development for Molecular Subtypes of Leukemia
Three novel therapeutic agents for the treatment of hematologic malignancies are under development at Cleveland Clinic Cancer Center.
Chipping Away at the Mystery of Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Jaroslaw Maciejewski, MD, PhD, discusses the prognostic relevance of CHIP mutations, the need for closer monitoring of patients who harbor them and current plans to establish Cleveland Clinic’s first CHIP clinic.
Mutations in Aplastic Anemia Can Predict Increased Risk of Myelodysplastic Syndromes
A new study shows that some genetic mutations found in patients with aplastic anemia can predict whether they will develop myelodysplastic syndromes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Exploiting Vulnerability of Impaired DNA Repair Creates New Therapeutic Strategy in Acute Myeloid Leukemia
Novel findings from a study of the PARP inhibitor olaparib are pointing to a new therapeutic strategy in the battle against acute myeloid leukemia, an extremely aggressive malignancy that commonly affects older adults and carries a grim prognosis.
Dynamics of Two Mutational Paths in the Progression of MDS
A new whole-exome sequencing study uncovers the dynamics of genetic alterations during progression of MDS to more aggressive acute leukemia and clarifies the impact of specific genetic defects on expected clinical behavior.
Cleveland Clinic Researcher Receives $5.5 Million Outstanding Investigator Award
Dr. Maciejewski will receive more than $5.5 million over the next seven years from the National Heart, Lung and Blood Institute of the NIH. His work examines the development of bone marrow failure syndromes (BMFS) and their molecular genetics.
A ‘Paradigm Shift’ in Conception of Aplastic Anemia
Cleveland Clinic researchers have identified gene mutations in some aplastic anemia patients that are associated with progression to myelodysplastic syndrome and/or acute myeloid leukemia. The mutations may trigger the immune response that results in aplastic anemia, and may also help mutated hematopoietic cells further proliferate.
Genetic Mutations Discovered That Drive Inherited Leukemias in Older Patients
Most cases of adult myeloid neoplasms, including myelodysplastic syndromes (MDS), have been presumed to occur sporadically. But Cleveland Clinic researchers identified a mutated gene, DDX41, associated with development of MDS, supporting the prospect of a familial predisposition mechanism behind such malignancies.
Expanding Clones Seen in Minority of Patients With Aplastic Anemia Treated With Eltrombopag
Cleveland Clinic researchers find that eltrombopag may contribute to expansion of clones with possible leukemogenic mutations in patients with aplastic anemia. A case control study is underway.